Identification

Name

Ergocalciferol

Accession Number

DB00153

Description

Ergocalciferol is an inactivated vitamin D analog.¹ It is synthesized by some plants in the presence of UVB light.⁶ The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.⁷

Ergocalciferol is considered the first vitamin D analog and is differentiated from cholecalciferol by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.³

The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.¹⁰

Type

Small Molecule

Groups

Approved, Nutraceutical

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Ergocalciferol (DB00153)

×

Close

Weight

Average: 396.6484
Monoisotopic: 396.33921603

Chemical Formula

C₂₈H₄₄O

Synonyms

• (3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
• (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
• (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
• Activated ergosterol
• Ercalciol
• Ergocalciferol
• Ergocalciférol
• Ergocalciferolum
• Oleovitamin D2
• Viosterol
• Vitamin D2
• Vitamina D2

Pharmacology

Indication

Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.^Label

Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.¹¹

Rickets is a condition produced due to a deficiency in vitamin D, calcium or phosphorus. However, this condition can also be related to renal diseases. It is characterized to present weak or soft bones.⁴

Familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin D metabolism in the kidneys. The presence of this condition can derive in the presence of osteomalacia, bone softening and rickets.¹²

Associated Conditions

• Hypophosphatemia, Familial
• Vitamin D Resistant Rickets
• Parathyroid deficiency

Associated Therapies

• Dietary and Nutritional Therapies

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

After the activation of the vitamin D receptor, some of the biological changes produced by ergocalciferol include mobilization and accretion of calcium and phosphorus in the bone, absorption of calcium and phosphorus in the intestine, and reabsorption of calcium and phosphorus in the kidney.⁷

Some other effects known to be produced due to the presence of vitamin D are osteoblast formation, fetus development, induction of pancreatic function, induction of neural function, improvement of immune function, cellular growth and cellular differentiation.⁷

When compared to its vitamin D counterpart cholecalciferol, ergocalciferol has been shown to present a reduced induction of calcidiol and hence, it is less potent.²

Ergocalciferol supplementation in patients with end-stage renal disease has been shown to generate a significant benefit in lab parameters of bone and mineral metabolism as well as improvement in glycemic control, serum albumin levels and reduced levels of inflammatory markers.¹

Mechanism of action

For its activity, ergocalciferol is required to be transformed to its major active circulating hydroxylated metabolite and transported to the target organs in order to bind to its target, the vitamin D receptor.⁷

The activation of the vitamin D receptor is part of the vitamin D endocrine system and it is described by the production of a change in the transcription rates of the vitamin D receptor target genes.⁷ The target genes in the DNA affected by the presence of ergocalciferol are called vitamin D response elements which are dependent on co-modulators.³

The vitamin D receptor is a transcription factor and member of the steroid hormone nuclear receptor family. It presents a DNA binding domain (VDRE) that, when activated, recruits coregulatory complexes to regulate the genomic activity.³

Additionally, ergocalciferol presents nongenomic effects such as the stimulation of intestinal calcium transport via transcaltachia.³

Target	Actions	Organism
AVitamin D3 receptor	agonist	Humans
NVoltage-dependent calcium channel	inducer	Humans

Absorption

Ergocalciferol is absorbed in the intestine and carried to the liver in chylomicrons. Its intestinal absorption does not present limitations unless the presence of conditions related to fat malabsorption.⁶ However, for absorption to take place, the presence of bile is required.¹³

Volume of distribution

The amount of circulating ergocalciferol is very limited as this compound is rapidly stored in fat tissue such as adipose tissue, liver and muscle. This is very obvious in reports that indicate that circulating ergocalciferol is significantly reduced in obese patients.⁶

Protein binding

Ergocalciferol is not found significantly distributed circulating in plasma. It is known to be found in its bound form to the vitamin D plasma protein.⁹ The parent compound of ergocalciferol does not bind directly to plasma proteins, however, 70-90% of its metabolites such as cholecalciferol and calcitriol are found in the bound form.⁵

Metabolism

Ergocalciferol is inactive and hence, the first step in the body is ruled by the conversion of this parent compound to 25-hydroxyvitamin D by the action of CYP2R1 followed by the generation of the major circulating metabolite, 1,25-dihydroxyvitamin D or calcitrol.⁶ The generation of this major metabolite is ruled by the activity of CYP27B1 which is a key 1-hydroxylase and CYP24A1 which is responsible for the 25-hydroxylation.³

As part of the minor metabolism, ergocalciferol is transformed into 25-hydroxyvitamin D in the liver by the activity of D-25-hydroxylase and CYP2R1. As well, the formation of 24(R),25dihydroxyvitamin D is performed mainly in the kidneys by the action of 25-(OH)D-1-hydroxylase and 25-(OH)D-24-hydroxylase.⁷

Additionally, there are reports indicating significant activity of 3-epimerase in the metabolism of ergocalciferol which modifies the hydroxy group in C3 from the alpha position to a beta. The epimers formed seemed to have a reduced affinity for the vitamin D plasma proteins and to the vitamin D receptor.³

An alternative activation metabolic pathway has been reported and this process is characterized by the activity of CYP11A1 and its hydroxylation in the C-20. This 20-hydroxylated vitamin D seems to have similar biological activity than calcitriol.³

Hover over products below to view reaction partners

• Ergocalciferol
  • 25-hydroxyvitamin D
    • Calcitrol
  • 24(R),25dihydroxyvitamin D
  • beta-ergocalciferol
  • 20-hydroxyvitamin D

Route of elimination

The active form of ergocalciferol, calcitrol, cannot be maintained for long periods in storage tissue mainly in periods of dietary or UVB deprivation.⁶ Therefore, ergocalciferol and its metabolites are excreted via the bile with a minor contribution of renal elimination. This major fecal elimination is explained due to the cubilin-megalin receptor system-mediated renal reuptake of vitamin D metabolites bound to vitamin D binding protein.¹⁴

Half-life

Ergocalciferol can be found circulation for 1-2 days. This quick turnover is presented due to hepatic conversion and uptake by fat and muscle cells where it is transformed to the active form.⁶

Clearance

There are no formal reports regarding the clearance rate of ergocalciferol. Due to the structural similarity, it is recommended to consult this parameter with cholecalciferol. On the other hand, the proposed renal clearance of calcitriol is of 31 ml/min.⁸

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

The reported LD50 for orally administered ergocalciferol in the rat is of 10 mg/kg.^MSDS Overdosage with this agent is reported to produce hypervitaminosis characterized by hypercalcemia, renal impairment, calcification of soft tissues, a decline in the rate of linear growth and increase in bone mineralization.¹⁵

Once an overdose state is registered, immediate withdrawal of vitamin D is required along with a calcium diet, generous intake of fluids and symptomatic treatment. The administration of loop diuretics is an option to increase renal calcium excretion. On the other hand, dialysis and administration of citrates, sulfates, phosphates, corticosteroids, EDTA and mithramycin are recommended.¹⁵

There haven't been long term studies analyzing the carcinogenic and mutagenic potential of ergocalciferol or its effects in fertility.

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Unlock Additional Data
Acetyldigitoxin	The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Acetyldigitoxin.
Alfacalcidol	The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Alfacalcidol.
Aluminum hydroxide	The serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.
Beclomethasone dipropionate	The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Beclomethasone dipropionate.
Bendroflumethiazide	The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Ergocalciferol.
Benzthiazide	The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Ergocalciferol.
Betamethasone	The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Betamethasone.
Betamethasone phosphate	The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Betamethasone phosphate.
Budesonide	The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Budesonide.
Calcifediol	The risk or severity of adverse effects can be increased when Calcifediol is combined with Ergocalciferol.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

No interactions found.

Products

Product Images

PreviousNext

International/Other Brands

Deltalin (Lilly)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
D-forte	Capsule		Oral	Euro Pharm International Canada Inc	2017-08-16	Not applicable
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Sanofi Aventis	1974-11-11	2017-02-28
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Avera McKennan Hospital	2016-02-05	2017-05-24
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Validus Pharmaceuticals LLC	2018-04-01	Not applicable
Drisdol	Capsule	1.25 mg/1	Oral	Sanofi Aventis	1974-11-11	2014-04-30
Drisdol	Capsule, liquid filled	1.25 mg/1	Oral	Validus Pharmaceuticals	1974-01-11	2018-03-31
Osto-D2	Capsule		Oral	Paladin Labs Inc	2008-02-08	2018-07-04
Radiostol Cap 50000iu	Capsule		Oral	Allen & Hanburys A Glaxo Canada Ltd. Co.	1989-12-15	1996-09-10

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Ergocalciferol	Capsule	1.25 mg/1	Oral	Breckenridge Pharmaceutical, Inc.	2009-08-17	2019-10-31
Ergocalciferol	Capsule	1.25 mg/1	Oral	Aphena Pharma Solutions - Tennessee, LLC	2009-05-20	Not applicable
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Rising Pharamceuticals, Inc	2010-07-23	Not applicable
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2016-06-15	Not applicable
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	bryant ranch prepack	2016-06-15	Not applicable
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	Bionpharma Inc.	2016-06-15	Not applicable
Ergocalciferol	Capsule	1.25 mg/1	Oral	Alembic Pharmaceuticals Inc.	2018-04-30	Not applicable
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	bryant ranch prepack	2016-06-15	Not applicable
Ergocalciferol	Capsule	1.25 mg/1	Oral	Golden State Medical Supply, Inc.	2011-11-15	Not applicable
Ergocalciferol	Capsule, liquid filled	1.25 mg/1	Oral	A-S Medication Solutions	2016-06-15	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Vitamin D 400 I.U. Tablets	Tablet		Oral	General Nutrition Canada Inc.	1997-04-18	2001-09-12

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Aquasol A & D Drops	Ergocalciferol (8000 unit) + Vitamin A (40000 unit)	Solution / drops	Oral	Rhone Poulenc Rorer	1993-12-31	1996-09-09
Cal/mag 2:1 With D	Ergocalciferol (100 unit) + Calcium (350 mg) + Magnesium (175 mg)	Tablet	Oral	Wn Pharmaceuticals Ltd.	1998-06-26	2000-02-02
Calcium and Magnesium Citrate With Vitamin D	Ergocalciferol (100 unit) + Calcium (275 mg) + Magnesium (137.5 mg)	Tablet	Oral	Sisu Inc.	1997-10-28	2005-07-13
Calcium Chelate Plus Vit D	Ergocalciferol (400 unit) + Calcium (50 mg)	Tablet	Oral	Hall Laboratories, Ltd.	1981-12-31	2003-09-11
Calcium Citrate W Vitamin D Tab	Ergocalciferol (100 unit) + Calcium citrate (250 mg)	Tablet	Oral	Nutri Dyn Products Ltd.	1994-12-31	1996-09-09
Calcium Magnesium 2:1 Tablets With Vitamin D	Ergocalciferol (200 unit) + Calcium (300 mg) + Magnesium (150 mg)	Tablet	Oral	Sisu Inc.	2004-01-30	2009-08-04
Calcium Magnesium Avec Vitamine D Et Zinc	Ergocalciferol (135 unit) + Calcium (335 mg) + Magnesium oxide (167 mg) + Zinc gluconate (10 mg)	Tablet	Oral	Les Aliments Nutri Source Inc.	1991-12-31	1996-09-09
Calcium Magnesium Plus Vitamin D Liquid	Ergocalciferol (2 unit) + Calcium gluconate (6 mg) + Inositol (.6 mg) + Magnesium citrate (3 mg)	Liquid	Oral	Jamp Pharma Corporation	2002-04-22	2003-02-05
Calcium Mg and Zn Capsules With Vitamin D	Ergocalciferol (100 unit) + Calcium (333.33 mg) + Magnesium (166.67 mg) + Zinc (6 mg)	Capsule	Oral	Rheingold Food International Ltd.	1995-12-31	2007-07-26
Calcium With Vitamin D2	Ergocalciferol (200 unit) + Calcium (250 mg)	Capsule	Oral	Sisu Inc.	2002-12-18	2008-07-25

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Se-Natal	Ergocalciferol (400 [iU]/1) + Calcium carbonate (250 mg/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Docusate sodium (50 mg/1) + Ferrous fumarate (90 mg/1) + Folic acid (1 mg/1) + Niacin (20 mg/1) + Niacinamide ascorbate (120 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin A acetate (4000 [iU]/1) + Zinc oxide (25 ug/1)	Tablet	Oral	Seton Pharmaceuticals	2009-04-16	2011-07-31

Categories

ATC Codes

A11CC01 — Ergocalciferol

• A11CC — Vitamin D and analogues
• A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
• A11 — VITAMINS
• A — ALIMENTARY TRACT AND METABOLISM

Drug Categories

• Alimentary Tract and Metabolism
• Bone Density Conservation Agents
• Calcium-Regulating Hormones and Agents
• Diet, Food, and Nutrition
• Food
• Food and Beverages
• Fused-Ring Compounds
• Growth Substances
• Lipids
• Micronutrients
• Physiological Phenomena
• Secosteroids
• Vitamin D and Analogues
• Vitamins
• Vitamins (Fat Soluble)

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Steroids and steroid derivatives

Sub Class

Vitamin D and derivatives

Direct Parent

Vitamin D and derivatives

Alternative Parents

Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives

Substituents

Alcohol / Aliphatic homopolycyclic compound / Cyclic alcohol / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Secondary alcohol / Triterpenoid

Molecular Framework

Aliphatic homopolycyclic compounds

External Descriptors

hydroxy seco-steroid, seco-ergostane, vitamin D (CHEBI:28934) / Vitamin D2 and derivatives, Fat-soluble vitamins (C05441) / Vitamin D2 and derivatives (LMST03010000)

Chemical Identifiers

UNII

VS041H42XC

CAS number

50-14-6

InChI Key

MECHNRXZTMCUDQ-RKHKHRCZSA-N

InChI

InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1

IUPAC Name

(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol

SMILES

CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C

References

Synthesis Reference

US5789397

General References

1. Porter A, Gilmartin C, Srisakul U, Arruda J, Akkina S: Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen. Am J Nephrol. 2013;37(6):568-74. doi: 10.1159/000351185. Epub 2013 May 30. [PubMed:23735861]
2. Lee JY, So TY, Thackray J: A review on vitamin d deficiency treatment in pediatric patients. J Pediatr Pharmacol Ther. 2013 Oct;18(4):277-91. doi: 10.5863/1551-6776-18.4.277. [PubMed:24719588]
3. Gallagher JC, Bikle DD: Vitamin D: Mechanisms of Action and Clinical Applications. Endocrinol Metab Clin North Am. 2017 Dec;46(4):xvii-xviii. doi: 10.1016/j.ecl.2017.09.001. Epub 2017 Sep 28. [PubMed:29080648]
4. Sahay M, Sahay RK: Refractory rickets in the tropics. J Pediatr Endocrinol Metab. 2010 Jun;23(6):597-601. [PubMed:20662333]
5. Hymoller L, Jensen SK: Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows. Domest Anim Endocrinol. 2017 Apr;59:44-52. doi: 10.1016/j.domaniend.2016.11.002. Epub 2016 Nov 16. [PubMed:27940098]
6. Coulston A. and Boushey C. (2008). Nutrition in the Prevention and Treatment of Disease (2nd ed.). Academic Press. [ISBN:978-012-374118-9]
7. Eitenmiller R., Ye L. and Landen W. (2008). Vitamin analysis for the health and food sciences (2nd ed.). Taylor and Francis. [ISBN:978-0-8493-9771-4]
8. Rajiv Kumar (1984). Vitamin D: Basic and Clinical Aspects. Martinus Nijhoff Publishing. [ISBN:978-1-4612-9793-2]
9. Speeckaert M., Speeckaert R., Geel N. and Delanghe J. (2014). Advances in Clinical Chemistry. Elsevier.
10. FDA approvals [Link]
11. Endocrine Web [Link]
12. NORD [Link]
13. Pediatric Pharmacotherapy [Link]
14. Pubmed books [Link]
15. Dailymed [Link]

External Links

Human Metabolome Database

HMDB0000900

KEGG Drug

D00187

KEGG Compound

C05441

PubChem Compound

5280793

PubChem Substance

46505053

ChemSpider

4444351

RxNav

4018

ChEBI

28934

ChEMBL

CHEMBL1536

ZINC

ZINC000004629876

Therapeutic Targets Database

DAP000291

PharmGKB

PA449484

PDBe Ligand

D2V

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Ergocalciferol

AHFS Codes

• 88:16.00 — Vitamin D

PDB Entries

3czh

FDA label

Download (125 KB)

MSDS

Download (167 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Treatment	Sarcoidosis / Vitamin D Insufficiency	1
4	Completed	Basic Science	25-Hydroxyvitamin D Concentration / Deficiency, Vitamin D	1
4	Completed	Treatment	Active Rheumatoid Arthritis (RA)	1
4	Completed	Treatment	BMI >30 kg/m2 / Deficiency, Vitamin D / Hyperparathyroidism, Secondary	1
4	Completed	Treatment	Calcium Nephrolithiasis / Deficiency, Vitamin D / Disorder of Vitamin D / Idiopathic Hypercalciuria / Urolithiasis	1
4	Completed	Treatment	Chronic Kidney Disease (CKD) / Deficiency, Vitamin D	1
4	Completed	Treatment	Chronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary	1
4	Completed	Treatment	Deficiency, Vitamin D	1
4	Completed	Treatment	Deficiency, Vitamin D / Hypercalcemia / Hypercalciuria / Osteopenia / Osteoporosis / Parathyroid deficiency	1
4	Completed	Treatment	Hip Fracture	1

Pharmacoeconomics

Manufacturers

• Eli lilly and co
• Sanofi aventis us llc
• Orit laboratories llc
• Sigmapharm laboratories llc
• Strides arcolab ltd
• Sun pharmaceutical industries inc
• Banner pharmacaps inc
• Chase chemical co lp
• Everylife
• Impax laboratories inc
• Lannett co inc
• Vitarine pharmaceuticals inc
• West ward pharmaceutical corp

Packagers

• Banner Pharmacaps Inc.
• Bayer Healthcare
• Breckenridge Pharmaceuticals
• Caraco Pharmaceutical Labs
• Gallipot
• Longs Drug Store
• Major Pharmaceuticals
• Optimum Pharmacueticals Inc.
• PD-Rx Pharmaceuticals Inc.
• Physicians Total Care Inc.
• Pliva Inc.
• Rising Pharmaceuticals
• Sanofi-Aventis Inc.
• Superior Pharmeceuticals
• Walgreen Co.
• Winthrop Us

Dosage Forms

Form	Route	Strength
Solution / drops	Oral
Capsule	Oral	1.25 mg/1
Capsule, liquid filled	Oral	1.25 mg/1
Liquid	Oral	0.2 mg/1mL
Liquid	Oral	8000 [iU]/1mL
Liquid	Oral
Tablet, effervescent	Oral
Injection, powder, lyophilized, for solution	Intravenous
Kit	Intravenous
Capsule	Oral
Liquid	Intravenous
Syrup	Oral
Capsule	Oral
Tablet	Oral
Tablet, extended release	Oral
Capsule	Oral	1.25 1/1
Tablet	Oral

Prices

Unit description	Cost	Unit
Ergocalciferol powder	234.4USD	g
Doral 15 mg tablet	3.41USD	tablet
Doral 7.5 mg tablet	3.37USD	tablet
Drisdol 50000 unit capsule	2.34USD	capsule
Drisdol 8288 unit/ml Liquid	0.48USD	ml
Vitamin d 400 unit softgel	0.04USD	softgel capsule
Longs vitamin d 400 unit tablet	0.03USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	115-117°C	Saxena P. 2007. Chemistry of alkaloids
boiling point (°C)	Decomposes	'MSDS'
water solubility	Insoluble	'MSDS'
logP	8.89	'MSDS'
pKa	6.35	Hart J. and Norman M. 1992. The Analyst.

Predicted Properties

Property	Value	Source
Water Solubility	0.000433 mg/mL	ALOGPS
logP	7.59	ALOGPS
logP	7.05	ChemAxon
logS	-6	ALOGPS
pKa (Strongest Acidic)	18.38	ChemAxon
pKa (Strongest Basic)	-1.3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	1	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	20.23 Å2	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	128.89 m3·mol-1	ChemAxon
Polarizability	50.73 Å3	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9428
Caco-2 permeable	+	0.8323
P-glycoprotein substrate	Substrate	0.6628
P-glycoprotein inhibitor I	Inhibitor	0.7614
P-glycoprotein inhibitor II	Non-inhibitor	0.8391
Renal organic cation transporter	Non-inhibitor	0.796
CYP450 2C9 substrate	Non-substrate	0.8432
CYP450 2D6 substrate	Non-substrate	0.9003
CYP450 3A4 substrate	Substrate	0.7362
CYP450 1A2 substrate	Non-inhibitor	0.9046
CYP450 2C9 inhibitor	Non-inhibitor	0.8924
CYP450 2D6 inhibitor	Non-inhibitor	0.9519
CYP450 2C19 inhibitor	Non-inhibitor	0.8784
CYP450 3A4 inhibitor	Non-inhibitor	0.8142
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8163
Ames test	Non AMES toxic	0.9401
Carcinogenicity	Non-carcinogens	0.9169
Biodegradation	Not ready biodegradable	0.9742
Rat acute toxicity	3.6931 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8502
hERG inhibition (predictor II)	Non-inhibitor	0.7513

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (9.78 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
GC-MS Spectrum - GC-MS (1 TMS)	GC-MS	splash10-003u-3911000000-dba9e396497310b31715
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
GC-MS Spectrum - GC-MS	GC-MS	splash10-003u-3911000000-dba9e396497310b31715
MS/MS Spectrum - Quattro_QQQ 10V, Positive	LC-MS/MS	splash10-0002-0129000000-77bd32807ec8ea97183b
MS/MS Spectrum - Quattro_QQQ 25V, Positive	LC-MS/MS	splash10-0601-5902000000-ae4a4363ac10f9f0feb7
MS/MS Spectrum - Quattro_QQQ 40V, Positive	LC-MS/MS	splash10-05mo-9800000000-1ea9f4fa17117a9e6515
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive	LC-MS/MS	splash10-01ot-9801000000-17d2120d47f9c718ea95
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-01ot-9801000000-c10341d61ee2d6369219
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on June 13, 2005 07:24 / Updated on August 10, 2020 08:11